Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...
Bristol-Myers Squibb's growth portfolio nears 60% of total revenues, growing 16% YoY, effectively offsetting patent cliff ...
Bristol Myers Squibb has the first positive phase 3 results under its belt for mezigdomide, a second experimental drug in its much-trumpeted celmod development programme for multiple myeloma. Interim ...
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results